• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Melanoma Trial Halted Early; Keytruda Betters Yervoy

Article

Currently, Keytruda is approved for patients with advanced melanoma previously treated with Yervoy and, in some patients, another type of drug as well. That second- and third-line status limits the number of patients eligible for the drug.

Advantage Merck in the melanoma immunotherapy race. The US-based company says its PD-1 drug Keytruda met its goals in a head-to-head study with Bristol-Myers Squibb's Yervoy (ipilimumab), dealing a blow to that company's growing immunotherapy franchise.

Even better, Keytruda bested Yervoy in previously untreated patients with advanced melanoma, a result that could lead to a bigger market for the Merck med.

Keytruda hit its primary endpoints not only for stalling cancer progression, but for extending patients' lives—so-called overall survival, a key measure for regulators, doctors and payers. Merck stopped the study, called KEYNOTE-006, after trial monitors decided the results were strong enough to prompt a halt.

Read the complete article on FiercePharma: http://bit.ly/1HGL4Ox

Related Videos
Mila Felder, MD, FACEP
Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute (FCS)
Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance (COA) and physician and partner of AO Multispecialty Clinic in Augusta, Georgia.
Dr Lucy Langer
Edward Arrowsmith, MD, MPH
Dr Kathi Mooney
Tiago Biachi de Castria, MD, PhD, Moffitt Cancer Center
Dr Guru Sonpavde
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.